The company recorded strong sales of consumer products, HIV and arthritis treatments.  Demand for its top five pharmaceutical markets grew by 6% overall.  However, it also faced the impact from loss of market exclusivity for Temodar and Nasonex. 2Q Revenues: $10.9 billion   -1% 2Q Earnings:   $2 billion  +120% YTD Revenues: $21,198 billion   -2% YTD Earnings: $3,764 billion  +48% Cost cutting efforts resulted in extremely strong earnings gains this quarter and overall sales remained strong des...